BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36575213)

  • 21. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
    Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
    BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
    Shah N; Zhai G; Knowles JA; Stockard CR; Grizzle WE; Fineberg N; Zhou T; Zinn KR; Rosenthal EL; Kim H
    Mol Imaging Biol; 2012 Apr; 14(2):237-44. PubMed ID: 21494920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A polyethylene glycol-conjugate of deoxycytidine analog, DFP-14927, produces potential antitumor effects on pancreatic tumor-xenograft murine models via inducing G2/M arrest.
    Ando H; Eshima K; Ishida T
    Eur J Pharmacol; 2023 Jul; 950():175758. PubMed ID: 37121563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
    Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
    Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
    Zechner D; Bürtin F; Albert AC; Zhang X; Kumstel S; Schönrogge M; Graffunder J; Shih HY; Müller S; Radecke T; Jaster R; Vollmar B
    Oncotarget; 2016 Aug; 7(35):56395-56407. PubMed ID: 27486761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
    Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
    World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.
    Ahn DW; Seo JK; Lee SH; Hwang JH; Lee JK; Ryu JK; Kim YT; Yoon YB
    Pancreas; 2012 Oct; 41(7):1048-57. PubMed ID: 22513291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
    Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
    Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
    Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
    Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways.
    Wang F; Tian X; Zhang Z; Ma Y; Xie X; Liang J; Yang C; Yang Y
    Int J Cancer; 2018 May; 142(9):1938-1951. PubMed ID: 29238973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
    Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
    Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
    Fujii Y; Kamachi H; Matsuzawa F; Mizukami T; Kobayashi N; Fukai M; Taketomi A
    Invest New Drugs; 2021 Oct; 39(5):1256-1266. PubMed ID: 33905019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.